Analyzing Onconetix (NASDAQ:ONCO) & Royalty Pharma (NASDAQ:RPRX)

Onconetix (NASDAQ:ONCO) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Onconetix and Royalty Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1	0	0	0	1.00
Royalty Pharma	0	0	7	0	3.00

Royalty Pharma has a consensus price target of $53.71, suggesting a potential downside of 2.37%. Given Royalty Pharma’s stronger consensus rating and higher probable upside, analysts clearly believe Royalty Pharma is more favorable than Onconetix.

Profitability

This table compares Onconetix and Royalty Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,316.28%	-101.08%	-47.34%
Royalty Pharma	33.88%	29.25%	14.71%

Earnings & Valuation

This table compares Onconetix and Royalty Pharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$735,198.00	1.61	-$14.03 million	$11.40	0.09
Royalty Pharma	$2.44 billion	12.98	$770.95 million	$1.47	37.43

Royalty Pharma has higher revenue and earnings than Onconetix. Onconetix is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

23.9% of Onconetix shares are owned by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are owned by institutional investors. 0.3% of Onconetix shares are owned by insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Onconetix has a beta of 2.72, indicating that its stock price is 172% more volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Summary

Royalty Pharma beats Onconetix on 12 of the 14 factors compared between the two stocks.

About Onconetix

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.